Status: Recruiting
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in the chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS) patients undergoing percutaneous coronary intervention (PCI) with the latest generation rapamycin drug-coated balloon (DCB) without stent implantation. The study aims to assess rates of ischemic and bleeding adverse events.
Participants needed: 2,170
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Gan LijunUpdated: May 19, 2026Locations: 3
Eligibility criteria
Age ≥ 18 years. [+7]
Stent implantation within 6 months prior to index percutaneous coronary interven... [+17]